Results 151 to 160 of about 23,554 (247)

Treatment With the Shaker Head‐Lift Exercise in Head and Neck Cancer Patients With Radiation‐Induced Dysphagia: 12‐Month Results on Swallowing Function From a Randomized, Controlled Trial

Head &Neck, EarlyView.
ABSTRACT Background Dysphagia is a common side‐effect after radiotherapy in head and neck cancer patients. This randomized study aimed to evaluate the effect of the shaker head‐lift exercise (HLE) after 12 months with flexible endoscopic evaluation of swallowing (FEES). Methods Patients were randomly assigned to the intervention (n = 30) or the control
Signe Rödseth Smith, Caterina Finizia, Kerstin Petersson, Lisa Tuomi   +3 more
wiley   +1 more source

Putting tobacco harm reduction in perspective: is it a viable alternative? [PDF]

Indian J Med Res, 2016
Jhanjee S.
europepmc   +1 more source

Global and local perspectives on tobacco harm reduction: what are the issues and where do we go from here? [PDF]

Harm Reduct J, 2018
Cox S, Dawkins L.
europepmc   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, EarlyView.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

A reduced exposure heated tobacco product was introduced then abruptly taken off United States shelves: results from a tobacco harm reduction natural experiment. [PDF]

Harm Reduct J
Noggle B, Ball KM, Vansickel AR.
europepmc   +1 more source

Correction to: Global and local perspectives on tobacco harm reduction: what are the issues and where do we go from here? [PDF]

Harm Reduct J, 2018
Cox S, Dawkins L.
europepmc   +1 more source

The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions

International Journal of Cancer, EarlyView.
ABSTRACT Lung cancer screening implementation is taking shape worldwide. Programme design requires specifying eligibility criteria, screening interval, and the optimal age range. We estimate benefits and harms of competing strategies, integrating NELSON results, smoking cessation interventions, contemporary treatment costs, and the management of ...
Koen de Nijs, Kevin ten Haaf, Dana Moldovanu, Juul Hubert, Isabelle van den Bosch, Carlijn van der Aalst, Harry J. de Koning   +6 more
wiley   +1 more source

Recommendations for the Appropriate Structure, Communication, and Investigation of Tobacco Harm Reduction Claims. An Official American Thoracic Society Policy Statement. [PDF]

Am J Respir Crit Care Med, 2018
Leone FT, Carlsen KH, Chooljian D, Crotty Alexander LE, Detterbeck FC, Eakin MN, Evers-Casey S, Farber HJ, Folan P, Kathuria H, Latzka K, McDermott S, McGrath-Morrow S, Moazed F, Munzer A, Neptune E, Pakhale S, Sachs DPL, Samet J, Sufian B, Upson D.   +20 more
europepmc   +1 more source

Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort

International Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei, Martina E. Schmidt, Philipp Zimmer, Patric Meyer, Andreas Schneeweiss, Karen Steindorf   +5 more
wiley   +1 more source

Ethical considerations of e-cigarette use for tobacco harm reduction. [PDF]

Respir Res, 2016
Franck C, Filion KB, Kimmelman J, Grad R, Eisenberg MJ.   +4 more
europepmc   +1 more source